当前位置: X-MOL 学术 › Biol. Blood Marrow Transplant. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Impact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry.
Biology of Blood and Marrow Transplantation ( IF 5.609 ) Pub Date : 2020-02-27 , DOI: 10.1016/j.bbmt.2020.01.030
Fernando Barroso Duarte 1 , Anna Thawanny Gadelha Moura 2 , Vaneuza Araújo Moreira Funke 3 , Virgílio Antônio Rensi Colturato 4 , Nelson Hamerschlak 5 , Neysimélia Costa Vilela 6 , Luiz Fernando Lopes 6 , Maria Cristina Martins de Almeida Macedo 7 , Afonso Celso Vigorito 8 , Rodolfo Daniel de Almeida Soares 9 , Alessandra Paz 10 , Mariana Stevenazzi 11 , Lilián Diaz 11 , Abrahao Elias Hallack Neto 12 , Gustavo Bettarello 13 , Breno Moreno de Gusmão 14 , Marco Aurélio Salvino 15 , Rodolfo Froes Calixto 16 , Maria Cláudia Rodrigues Moreira 17 , Gustavo Machado Teixeira 18 , Cinthya Corrêa da Silva 19 , Anderson João Simioni 19 , Romélia Pinheiro Gonçalves Lemes 2
Affiliation  

It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS. We retrospectively analyzed data from the Latin American registry of 258 patients from 17 Latin American centers who underwent HSCT from 1988 to 2019. Our data showed that there was pre-HSCT. We detected no significant difference regarding the impact on overall survival of treated and untreated patients before HSCT. Despite these data, the type of previous treatment among treated patients showed a significant difference in overall survival. Treatment with hypomethylating agents together with pre-HSCT chemotherapy seems to result in better survival of the studied population. These data correspond to the first results obtained through cooperative work between various centers in Latin America comparing the different approaches to patients and reflecting their reality and challenges. Therefore, the selection of pretransplant bridge therapy should be analyzed and focus given primarily to those approaches that result in better survival of patients with MDS.

中文翻译:

骨髓增生异常综合症患者同种异体移植造血干细胞治疗前的影响:拉丁美洲骨髓移植登记系统的结果。

已经提出,在强烈的增生异常综合征(MDS)患者的治疗中,采用强力化学疗法和/或低甲基化药物的桥接治疗,然后进行造血干细胞移植(HSCT)可能是有价值的。但是,这种方法对HSCT结局的影响仍然不清楚。因此,我们的目的是研究HSDS前治疗对MDS患者的影响。我们回顾性分析了来自拉丁美洲17个拉丁美洲中心1988年至2019年接受HSCT的258例患者的拉丁美洲注册中心的数据。我们的数据显示,存在HSCT前。我们未发现在HSCT之前对已治疗和未治疗患者总体生存的影响有显着差异。尽管有这些数据,在接受治疗的患者中,先前治疗的类型显示出总体生存率的显着差异。用次甲基化剂与HSCT之前的化学疗法一起治疗似乎可以提高研究人群的生存率。这些数据对应于拉丁美洲各个中心之间通过合作工作获得的第一批结果,比较了针对患者的不同方法并反映了他们的现实和挑战。因此,应分析移植前桥疗法的选择,并将重点主要放在那些可导致MDS患者更好生存的方法上。这些数据对应于拉丁美洲各个中心之间通过合作工作获得的第一批结果,比较了针对患者的不同方法并反映了他们的现实和挑战。因此,应分析移植前桥疗法的选择,并将重点主要放在那些可导致MDS患者更好生存的方法上。这些数据对应于拉丁美洲各个中心之间通过合作工作获得的第一批结果,比较了针对患者的不同方法并反映了他们的现实和挑战。因此,应分析移植前桥疗法的选择,并将重点主要放在那些可导致MDS患者更好生存的方法上。
更新日期:2020-02-27
down
wechat
bug